The American Cancer Society medical and editorial content team. February 28, 2018. http://www.cancer.org/cancer/acs-medical-content-and-news-staff.html. Accessed 6 June 2022.

Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–81. https://doi.org/10.1053/j.seminoncol.2016.11.004.

Article  PubMed  PubMed Central  Google Scholar 

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52–61.

CAS  Article  Google Scholar 

Yang P, Qu Y, Wang M, et al. Pathogenesis and treatment of multiple myeloma. MedComm (2020). 2022;3(2):146. https://doi.org/10.1002/mco2.146.

CAS  Article  Google Scholar 

Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–93. https://doi.org/10.1158/1078-0432.CCR-16-2895.

Article  PubMed  Google Scholar 

Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016;172:685–98. https://doi.org/10.1111/bjh.13889.

Article  PubMed  Google Scholar 

Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers (Basel). 2021;13(20):5154. https://doi.org/10.3390/cancers13205154.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17(5):503–15. https://doi.org/10.2217/fon-2020-1003.

CAS  Article  PubMed  Google Scholar 

Hagiwara M, Panjabi S, Delea T, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma in the US. Leuk Lymphoma. 2020;61(1):47–55. https://doi.org/10.1080/10428194.2019.1648802.

Article  PubMed  Google Scholar 

Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34:2317–32. https://doi.org/10.1038/s41375-020-0930-x.

CAS  Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Accessed June 6, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma.

U.S. Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma. Accessed May 26, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-abecma-idecabtagene-vicleucel-first-fda-approved-cell-based#:~:text=On%20March%2026%2C%202021%2C%20the,an%20anti%2DCD38%20monoclonal%20antibody.

Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma. Expert Rev Hematol. 2022. https://doi.org/10.1080/17474086.2022.2081147.

Article  PubMed  Google Scholar 

Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130(24):2594–602. https://doi.org/10.1182/blood-2017-06-793869.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37(10):1779–88. https://doi.org/10.1080/03007995.2021.1953456.

CAS  Article  PubMed  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24. https://doi.org/10.1016/S0140-6736(21)00933-8.

CAS  Article  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.

CAS  Article  PubMed  Google Scholar 

U.S. Census Bureau. 2022 National population estimates. 2022. https://www.census.gov/data-tools/demo/idb/#/country?COUNTRY_YEAR=2022&COUNTRY_YR_ANIM=2022. Accessed 12 May 2022.

Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9(1):3. https://doi.org/10.3390/medsci9010003.

CAS  Article  Google Scholar 

IBM Watson. IBM Micromedex. RED BOOK Online. [Database]. 2022. http://www.micromedexsolutions.com. Accessed 20 May 2022

Centers for Medicare & Medicaid Services. 2022. ASP Drug Pricing Files [Internet]. 2022; [cited 2022 May 10]. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files.

Centers for Medicare & Medicaid Services. Fiscal Year (FY) 2021 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) Final Rule (CMS-1735-F). https://www.cms.gov/newsroom/fact-sheets/fiscal-year-fy-2021-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute-0. Accessed 26 May 2022.

Centers for Medicare & Medicaid Services. Physician Fee Schedule Final Rule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched. Published 2022. Accessed.

U.S. Bureau of Labor Statistics. Consumer price index. https://www.bls.gov/cpi. Accessed 23 May 2022

Jagannath S, Joseph N, Crivera C, Jackson CC, Valluri S, Cost P, Phelps H, Slowik R, Klein T, Xueting Yu, Smolen L, Cohen AD. Total CAR-T cost of care beyond the price of CAR-T cell therapy in patients with multiple myeloma. Blood. 2021;138(Supplement 1):4964. https://doi.org/10.1182/blood-2021-153438.

Article  Google Scholar 

Lee SJ, McQueen RB, Beinfeld M, Fluetsch N, Whittington MD, Pearson SD, Ollendorf DA. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; Final Evidence Report. Institute for Clinical and Economic Review, May 11, 2021. https://icer.org/assessment/multiple-myeloma-2021/#timeline

Hari P, Nguyen A, McGarvey N, et al. 1598 Healthcare resource utilization and cost of cytokine release syndrome and neurotoxicity in patients with relapsed and refractory multiple myeloma receiving the BCMA-directed chimeric antigen receptor T Cell therapy idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Trial. American Society of Hematology; 2020.

Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benef. 2015;8(4):204–15.

Google Scholar 

Anti B-Cell Maturation Antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; response to public comments on draft evidence report, April 5,2021. https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Response-to-Comments_040521.pdf

Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37. https://doi.org/10.1056/NEJMoa1817226.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Cruz-Ramos M, García-Foncillas J. CAR-T cell and personalized medicine. Adv Exp Med Biol. 2019;1168:131–45. https://doi.org/10.1007/978-3-030-24100-1_9.

CAS  Article  PubMed  Google Scholar 

Shimabukuro-Vornhagen A, Böll B, Schellongowski P, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin. 2022;72(1):78–93. https://doi.org/10.3322/caac.21702.

Article  PubMed  Google Scholar